use of active management of the third stage of labor in
play

Use of Active Management of the Third Stage of Labor in Eleven - PowerPoint PPT Presentation

Use of Active Management of the Third Stage of Labor in Eleven Developing Countries Deborah Armbruster Senior Maternal and Newborn Health Advisor Bureau for Global Health, USAID Reality Check: Challenges and Innovations in Addressing the


  1. Use of Active Management of the Third Stage of Labor in Eleven Developing Countries Deborah Armbruster Senior Maternal and Newborn Health Advisor Bureau for Global Health, USAID Reality Check: Challenges and Innovations in Addressing the PPH Agenda Washington, DC January 25, 2011

  2. Active Management of the Third Stage of Labor (AMTSL) What is AMTSL? • High impact, evidence-based intervention – 2 seminal RCTs and many additional studies support evidence – Reduces postpartum hemorrhage (PPH) by up to 60% • 3 components – Administration of a uterotonic agent (oxytocin is the drug of choice) – Controlled cord traction – Uterine massage after delivery of the placenta

  3. History and Focus on AMTSL • 20 yrs of use in G. Britain and Commonwealth • Not used in US • USAID created PPH Initiative – Initial focus on AMTSL – Added community-based intervention with miso • 4 country projects, POPPHI, integration into MH projects • Is on the global agenda; many partners

  4. AMTSL national surveys in 11 countries – 2005-2010 75 Indonesia 32 Ethiopia 29 With support, AMTSL coverage increased rapidly in Cirebon district Benin 17 of Indonesia Bangladesh 16 Tanzania 7 Guatemala National 7 coverage of Honduras 5 AMTSL is Uganda 5 low in all Ghana 3 countries El Salvador 3 Nicaragua 0.3 0 20 40 60 80 100 Percent National USAID ‐ Supported district POPPHI Project Multi-Country Survey. http://www.pphprevention.org/briefs_newsletters.php

  5. Percent of observed deliveries w/ uterotonic given during 3 rd /4 th stages of labor and correct use of AMTSL (1 mn) 100.0 99.7 97.6 100.0 95.6 95.6 92.6 86.7 90.0 80.0 70.0 60.0 60.0 % o f d eliveries 50.0 40.0 31.8 29.0 30.0 22.8 20.0 7.1 6.7 10.0 4.5 2.6 0.3 0.0 Benin Tanzania Ethiopia El Salvador Guatemala Honduras Nicaragua Indonesia Received uterotonic 3rd/4th stage AMTSL (1 min)

  6. Percent of observed deliveries with uterine massage following delivery of placenta 100.0 88.3 87.6 90.0 79.2 77.8 77.8 80.0 72.0 70.0 62.0 60.0 % o f d e liv e rie s 54.0 50.0 38.7 40.0 36.4 31.6 30.0 23.5 20.0 10.2 10.0 6.1 NA NA 0.0 Benin Tanzania Ethiopia El Salvador Guatemala Honduras Nicaragua Indonesia Immediate massage after delivery of baby Massage, plus palpation

  7. Critical Elements for AMTSL Expansion Policies, POLICY guidelines, Awareness & protocols, endorsement standards in of national place expansion PROVIDER Standardized Improved All women are pre- & in- provider service knowledge, skills Reduced PPH offered and training & motivation Reduced receive PPH mortality prevention intervention LOGISTICS (DRUGS & SUPPLIES) Appropriate amount of Drug drugs procured, logistics appropriately stored, & in place available for all births MONITORING/SUPERVISION MIS & supervision system in place

  8. Lessons learned: AMTSL • What is NOT so effective in increasing use of AMTSL? - ONLY changing policies - ONLY training providers - ONLY having drugs available - ONLY recording data and monitoring

  9. Lessons Learned: AMTSL • Need creative and alternative ways to: - Increase the practice of AMTSL - Ensure competence of providers - Provide support & supervision - Ensure drugs are available for AMTSL - Record & collect data

  10. Think outside the box • Try new innovations; engage your local partners to create solutions • Recognize the critical importance of the combined efforts of the MOH and all groups within a country to scale-up AMTSL for impact • Are we having an impact? Are we saving lives? We need indicators, record keeping and data collection efforts to let us know.

  11. Noteworthy News and Issues • AMTSL trial ( WHO multi-centre (8)) will report results in early March 2011. Could find that controlled cord traction not needed • Oxytocin potency may be more of a concern that previously thought – watch for new study results to come out soon • Will that make oxytocin in Uniject with its TTI more popular? Will this push for increased use of misoprostol? • Miso is available, miso is being used… are providers and the public properly educated on its use?

  12. Thank you Join us in Addis Ababa, Ethiopia Feb. 21-25 Africa Regional Meeting on Interventions for Impact in Essential Obstetric and Newborn Care

Recommend


More recommend